No products in the cart.
G-CSF-R/CSF3R: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of G-CSF-R/CSF3R. The page also collects GeneMedi’s different modalities and formats products for G-CSF-R in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the G-CSF-R target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is the receptor for colony stimulating factor 3, a cytokine that controls the production, differentiation, and function of granulocytes. The encoded protein, which is a member of the family of cytokine receptors, may also function in some cell surface adhesion or recognition processes. Alternatively spliced transcript variants have been described. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia. [provided by RefSeq, Aug 2010]
|
Target ID |
GM-T98913
|
|
Target Name |
G-CSF-R
|
|
Gene ID |
1441
|
|
Gene Official Name |
CSF3R
|
|
Gene Alias |
CD114, GCSFR, SCN7
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
Therapeutics Target, Immuno-oncology Target, INN Index
|
Pre-made G-CSF-R-specific INN-index biosimilar (antibody&conjugates)-eflapegrastim, efbemalenograstim alfa, filgrastim, balugrastim, Anumigilimab, pegfilgrastim
Anti-G-CSF-R therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Filters
Sort results
Reset
Apply
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
|---|---|---|---|---|---|---|
Pre-Made Anumigilimab biosimilar, Whole mAb, Anti-CSF3R/G-CSF-R Antibody: Anti-CD114/GCSFR/SCN7 therapeutic antibody |
Anumigilimab |
NA |
CSF3R |
Whole mAb |
||
Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 |
balugrastim |
NA |
CSF3R |
Fusion Protein |
||
Pre-Made Efbemalenograstim Alfa Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CD114 |
efbemalenograstim alfa |
NA |
CSF3R |
Fusion Protein |
||
Pre-Made Filgrastim Biosimilar, Recombinant Protein targeting CSF3R: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 |
filgrastim |
NA |
CSF3R |
Recombinant Protein |
Anti-CSF3R/ G-CSF-R/ CD114 antibody for FACS & in-vivo assay| GMab
Pre-made anti-G-CSF-R benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-G-CSF-R mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filters
Sort results
Reset
Apply
Cat No. | Antibody Name | Format | Classified by tag | Order
|
|---|---|---|---|---|
Anti-G-CSF-R/CSF3R monoclonal antibody |
mab |
FACS/Biofunctional Antibody, Therapeutics Target antibody |
